Observational studyRMD open2026

Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study.

Helena Marzo-Ortega et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.